Two Sigma Investments
NKTR icon

Two Sigma Investments’s Nektar Therapeutics NKTR Stock Holding History

Two Sigma Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,693
Closed -$1.97M – 3465
2018
Q2 		$1.97M Buy
+2,693
New +$3.11M 0.01% 1620
2017
Q4 		– Sell
-627
Closed -$226K – 3343
2017
Q3 		$226K Buy
+627
New +$196K ﹤0.01% 2543

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments's NKTR Position: Q1 2026 in Review

Two Sigma Investments increased its Nektar Therapeutics (NKTR) stake by 97% in Q1 2026, buying an estimated $26.1M and bringing the position to 930,741 shares worth $67M. The position accounts for 0.05% of the portfolio, ranked #392.

Two Sigma Investments first reported a position in NKTR in Q3 2013 and has held it in 35 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Two Sigma Investments held 930,741 shares of Nektar Therapeutics worth $67M as of Q1 2026.
  • Two Sigma Investments bought 457,727 Nektar Therapeutics shares in Q1 2026, an estimated $26.1M.
  • Nektar Therapeutics made up 0.05% of Two Sigma Investments's portfolio in Q1 2026, its #392 holding.
  • Two Sigma Investments first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 35 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.